erlotinib hydrochloride has been researched along with hydroxychloroquine in 2 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (hydroxychloroquine) | Trials (hydroxychloroquine) | Recent Studies (post-2010) (hydroxychloroquine) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 5,885 | 474 | 4,041 |
| Protein | Taxonomy | erlotinib hydrochloride (IC50) | hydroxychloroquine (IC50) |
|---|---|---|---|
| Muscarinic acetylcholine receptor M2 | Homo sapiens (human) | 2.951 | |
| Alpha-1D adrenergic receptor | Homo sapiens (human) | 4.772 | |
| Toll-like receptor 9 | Homo sapiens (human) | 0.11 | |
| Toll-like receptor 7 | Homo sapiens (human) | 3.4 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Leung, LS; Marmor, MF; Neal, JW; Sequist, LV; Wakelee, HA | 1 |
| Huang, K; Liu, D | 1 |
1 trial(s) available for erlotinib hydrochloride and hydroxychloroquine
| Article | Year |
|---|---|
Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.
Topics: Aged; Antineoplastic Agents; Antirheumatic Agents; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; Electroretinography; Erlotinib Hydrochloride; Female; Fluorescein Angiography; Humans; Hydroxychloroquine; Lung Neoplasms; Male; Middle Aged; Retina; Retinal Diseases; Retrospective Studies; Tomography, Optical Coherence; Visual Field Tests; Visual Fields | 2015 |
1 other study(ies) available for erlotinib hydrochloride and hydroxychloroquine
| Article | Year |
|---|---|
Targeting non-canonical autophagy overcomes erlotinib resistance in tongue cancer.
Topics: Adenine; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Autophagy-Related Protein 5; Beclin-1; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; Erlotinib Hydrochloride; Humans; Hydroxychloroquine; RNA, Small Interfering; Sirolimus; Tongue Neoplasms; Up-Regulation | 2016 |